Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.

Journal Article

This prospective randomized study in nonhormonally responsive adenocarcinoma of the prostate shows that response rates to melphalan vs cyclophosphamide groups were virtually identical.

Full Text

Duke Authors

Cited Authors

  • Graham, SD; Walker, A; Cox, EB; Laszlo, J; Berry, WR; Paulson, DF

Published Date

  • November 1986

Published In

Volume / Issue

  • 28 / 5

Start / End Page

  • 404 - 408

PubMed ID

  • 3538611

International Standard Serial Number (ISSN)

  • 0090-4295


  • eng

Conference Location

  • United States